CanadaBis Capital (TSXV:CANB) Tariff Resilience Score: 5/10 (As of Jul. 11, 2026)


What is CanadaBis Capital Tariff Resilience Score?

CanadaBis Capital TSXV:CANB Tariff Resilience Score is 5 as of Jul. 11, 2026. The stock has 6 warning signs investors should review. Among 1,029 Drug Manufacturers companies, CanadaBis Capital ranks better than 84.45% on this metric.

CanadaBis Capital has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

CanadaBis Capital has CanadaBis Capital, involved in cannabis, faces moderate tariff risks due to cross-border trade of equipment and supplies. The industry has seen some tariff impacts, but regulatory changes and domestic focus provide partial mitigation.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes CanadaBis Capital might have Average Resilient.

CanadaBis Capital  (TSXV:CANB) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

CanadaBis Capital Tariff Resilience Score Related Terms

TSXV:CANB vs NPHC, BSPK, CPMD: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, CanadaBis Capital's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CanadaBis Capital Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CanadaBis Capital's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where CanadaBis Capital's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 5 mean?
CanadaBis Capital (TSXV:CANB) has a Tariff Resilience Score of 5 as of Jul. 11, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, CanadaBis Capital ranks #160 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 15.5%.
Is CanadaBis Capital's Tariff Resilience Score too high?
CanadaBis Capital's current Tariff Resilience Score is 5. Based on the distribution chart, CanadaBis Capital ranks #160 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does CanadaBis Capital's Tariff Resilience Score compare to NPHC and BSPK?
According to the Drug Manufacturers industry distribution chart, CanadaBis Capital ranks #160 out of 1029 companies for Tariff Resilience Score. This places CanadaBis Capital in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. CanadaBis Capital's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanadaBis Capital stock overvalued right now?
CanadaBis Capital (TSXV:CANB) has a current Tariff Resilience Score of 5. The stock's GF Value™ is C$0.07, compared to a current price of C$0.02 — trading 78.6% below its estimated fair value. The current Tariff Resilience Score is 5. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For CanadaBis Capital (TSXV:CANB), the current Tariff Resilience Score is 5 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CanadaBis Capital Business Description

Other Exchanges CNADF:USA
Address 255C Clearview Drive, Red Deer County, Red Deer, AB, CAN, T4E 3B6
CanadaBis Capital Inc is a vertically integrated cannabis company. The firm engages in the production and sale of recreational cannabis. Its product line consists of Stigma Roots. It operates in three segments: wholesale, retail, and extract. The wholesale segment cultivates and distributes cannabis and cannabis products to and through, provincial liquor and cannabis boards. Retail segment involves sale of cannabis and cannabis-related products to end consumers on-premises owned and operated by the Company. Extract segment provides cannabinoid extraction services to other licensed producers. The company generates maximum of its revenue from Extract Segment.